Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation and Kidney Transplantation in the Treatment of Schimke Immuno-osseous Dysplasia
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the treatment of Schimke immuno-osseous dysplasia
• 1\. Diagnosed as SIOD and was in stage 5 of chronic kidney disease
• 2\. Having allogeneic HSCT indications, at least suitable donors (relatives) for haploidentical allogeneic transplantation and kidneys from stem cell transplantation donors;
• 3\. serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range.
• 4\. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
• 5\. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%；
• 6\. Estimated survival time ≥ 3 months;
• 7\. ECOG performance status 0 to 1;
• 8\. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
• 9\. Those who voluntarily participated in this trial and provided informed consent;